Kaskela Law is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) (“Gyre”) on behalf of the company’s long-term investors.
The investigation seeks to determine whether Gyre and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.
Gyre shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at [email protected], or by completing the form on this page.